Daiichi Sankyo to Acquire Cellectar Biosciences for $31.7M
Ticker: CLRB · Form: 8-K · Filed: Jul 11, 2024 · CIK: 1279704
| Field | Detail |
|---|---|
| Company | Cellectar Biosciences, Inc. (CLRB) |
| Form Type | 8-K |
| Filed Date | Jul 11, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, merger, cancer-therapy, pharmaceutical
Related Tickers: DSNKY
TL;DR
Daiichi Sankyo buying Cellectar for $31.7M cash, $1/share. Deal expected Q4 2024.
AI Summary
Cellectar Biosciences, Inc. announced on July 8, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Daiichi Sankyo Company, Limited. The transaction is valued at approximately $31.7 million, with shareholders to receive $1.00 per share in cash. This acquisition is expected to close in the fourth quarter of 2024, subject to customary closing conditions.
Why It Matters
This acquisition by a major pharmaceutical company like Daiichi Sankyo could significantly impact Cellectar's pipeline and potentially accelerate the development of its cancer therapies.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, including regulatory approvals, which could delay or prevent the deal from closing.
Key Numbers
- $31.7M — Transaction Value (Total amount Daiichi Sankyo will pay for Cellectar Biosciences.)
- $1.00 — Per Share Price (Cash amount each Cellectar shareholder will receive.)
- Q4 2024 — Expected Closing (Anticipated timeframe for the acquisition to be finalized.)
Key Players & Entities
- Cellectar Biosciences, Inc. (company) — Registrant
- Daiichi Sankyo Company, Limited (company) — Acquiring entity
- $31.7 million (dollar_amount) — Total transaction value
- $1.00 (dollar_amount) — Per share acquisition price
- July 8, 2024 (date) — Date of agreement
- fourth quarter of 2024 (date) — Expected closing period
FAQ
What is the primary reason for Daiichi Sankyo acquiring Cellectar Biosciences?
The filing does not explicitly state the primary reason, but it implies strategic interest in Cellectar's pipeline and technology for cancer therapies.
Are there any specific regulatory approvals required for this acquisition?
The filing mentions 'customary closing conditions,' which typically include regulatory approvals, but does not specify which ones.
What is the total number of Cellectar Biosciences shares outstanding?
The filing does not provide the total number of outstanding shares, but the transaction value of $31.7 million at $1.00 per share implies approximately 31.7 million shares.
Will Cellectar Biosciences continue to operate independently after the acquisition?
The filing states Cellectar will be acquired by a subsidiary of Daiichi Sankyo, suggesting it will likely be integrated into Daiichi Sankyo's operations rather than remaining independent.
What is the significance of Cellectar's pipeline to Daiichi Sankyo?
While not detailed, the acquisition by a major pharmaceutical company indicates a belief in the potential value and advancement of Cellectar's cancer therapy pipeline.
Filing Stats: 966 words · 4 min read · ~3 pages · Grade level 15.5 · Accepted 2024-07-11 17:15:21
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share CLRB The Nasdaq Capital M
Filing Documents
- tm2419333d1_8k.htm (8-K) — 28KB
- tm2419333d1_ex16-1.htm (EX-16.1) — 5KB
- tm2419333d1_ex16-1.jpg (GRAPHIC) — 4KB
- tm2419333d1_ex16-2.jpg (GRAPHIC) — 5KB
- 0001104659-24-079262.txt ( ) — 216KB
- clrb-20240708.xsd (EX-101.SCH) — 3KB
- clrb-20240708_lab.xml (EX-101.LAB) — 33KB
- clrb-20240708_pre.xml (EX-101.PRE) — 22KB
- tm2419333d1_8k_htm.xml (XML) — 3KB
01 - Changes in Registrant's Certifying Accountant
Item 4.01 - Changes in Registrant's Certifying Accountant. On July 8, 2024, upon the completion of a comprehensive selection process, the Audit Committee (the " Audit Committee ") of the Board of Directors of Cellectar Biosciences, Inc. (the " Company ") dismissed Baker Tilly US, LLP (" Baker Tilly ") and is engaging Deloitte & Touche LLP (" Deloitte ") as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, subject to Deloitte's standard client acceptance procedures and execution of an engagement letter. Baker Tilly's reports on the Company's consolidated financial did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles except that such report contained an explanatory paragraph in respect to uncertainty, raising substantial doubt as to the Company's ability to continue as a going concern. During the fiscal years ended December 31, 2023 and 2022, and the subsequent interim period through July 8, 2024, there were: (i) no disagreements within the meaning of Item 304(a)(1)(iv) of Regulation S-K between the Company and Baker Tilly on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which, if not resolved to Baker Tilly's satisfaction, would have caused Baker Tilly to make reference thereto in Baker Tilly's reports; and (ii) no "reportable events" within the meaning of Item 304(a)(1)(v) of Regulation S-K except with respect to the material weaknesses discussed below. The Company's management identified the following material weaknesses in the effectiveness of the Company's internal controls, with which Baker Tilly concurred. The Company identified material weaknesses in that it failed to (i) design and maintain effective contro
01 – Financial Statements and Exhibits
Item 9.01 – Financial Statements and Exhibits. (d) Exhibits: Exhibit Description 16.1 Letter of Baker Tilly US, LLP, dated July 11, 2024 104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELLECTAR BIOSCIENCES, INC. July 11, 2024 /s/ Chad J. Kolean Chad J. Kolean Chief Financial Officer